Zinc intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
Principal Investigator
Name
Yun-Bing Wang
Degrees
ph.D.
Institution
The second affiliated hospital of Chongqing Medical University
Position Title
Dr.
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-650
Initial CDAS Request Approval
Jul 17, 2020
Title
Zinc intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
Summary
Zinc is an essential micronutrient, whose abnormality may be involved in the development and progression of cancer [1]. A nested case-control study found there was a strong inverse association between serum zinc and risk of primary liver cancer (PLC) and zinc might prevent the incidence of primary liver cancer [2]. One animal model study found the hepatic zinc concentrations was significantly lower in models with liver tumor than in control group [3].
Previous studies indicated that zinc might play a role in inhibiting the incidence of PLC. However, whether zinc intake could reduce the incidence of PLC is unclear. Therefore, we used the data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial to prospectively explore this relationship. Besides, we also explored the relationship of zinc intake and the mortality of PLC. The findings of our research might be helpful to provide suggestions for the prevention of PLC.
References:
1. Li D, Stovall DB, Wang W, Sui G. Advances of Zinc Signaling Studies in Prostate Cancer. INT J MOL SCI 2020;21.
2. Stepien M, Hughes DJ, Hybsier S, Bamia C, Tjønneland A, Overvad K, Affret A, His M, Boutron-Ruault MC, Katzke V, Kühn T, Aleksandrova K, et al. Circulating copper and zinc levels and risk of hepatobiliary cancers in Europeans. Br J Cancer 2017;116:688-96.
3. Harro CC, Smedley RC, Buchweitz JP, Langlois DK. Hepatic copper and other trace mineral concentrations in dogs with hepatocellular carcinoma. J VET INTERN MED 2019;33:2193-9.
Previous studies indicated that zinc might play a role in inhibiting the incidence of PLC. However, whether zinc intake could reduce the incidence of PLC is unclear. Therefore, we used the data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial to prospectively explore this relationship. Besides, we also explored the relationship of zinc intake and the mortality of PLC. The findings of our research might be helpful to provide suggestions for the prevention of PLC.
References:
1. Li D, Stovall DB, Wang W, Sui G. Advances of Zinc Signaling Studies in Prostate Cancer. INT J MOL SCI 2020;21.
2. Stepien M, Hughes DJ, Hybsier S, Bamia C, Tjønneland A, Overvad K, Affret A, His M, Boutron-Ruault MC, Katzke V, Kühn T, Aleksandrova K, et al. Circulating copper and zinc levels and risk of hepatobiliary cancers in Europeans. Br J Cancer 2017;116:688-96.
3. Harro CC, Smedley RC, Buchweitz JP, Langlois DK. Hepatic copper and other trace mineral concentrations in dogs with hepatocellular carcinoma. J VET INTERN MED 2019;33:2193-9.
Aims
1. To explore the relationship of zinc intake and PLC incidence and mortality.
2. To explore the potential confounding factors that might influence the relationship of zinc intake and PLC incidence and mortality.
Collaborators
1. Jian-Ying Zhang, Department of Radiology, Chongqing General Hospital, University of Chinese Academy of Sciences, Chongqing, China;
2. Chun-Mu Miao, Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China;
3. Rong Ma, Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.